argenx SE has named Karen Massey, chief operating officer, as chief executive officer and Tim Van Hauwermeiren, current CEO and a co-founder of argenx, as chairman, succeeding Peter Verhaeghe. The appointments are subject to shareholder approval at the annual general meeting on 6 May 2026. The leadership changes will support the next phase of growth, ‘Vision 2030,’ of the immunology company, whose lead product Vyvgart (efgartigimod) is in high demand.
Ms Massey joined argenx three years ago and was previously a senior executive at the Genentech unit of Roche. At argenx she has accelerated Vyvgart’s launch, built a robust commercial engine and driven company culture and teams. Mr Van Hauwermeiren will support long-term strategy and innovation and lead the board’s evolution for argenx’s next phase of growth.
argenx announced the appointments on 5 January 2026.
Copyright 2026 Evernow Publishing Ltd.